Chicago 2014 TFQO: Darren Walters COI #317 EVREV 1: Darren Walters COI #317 EVREV 2: Chris Ghaemmaghami COI #60 Taskforce: Acute Coronary Syndrome In STEMI.

Slides:



Advertisements
Similar presentations
Dallas 2015 TFQO: Tony Scott #138 EVREV 1: Tony Scott #138 EVREV 2: Anthony Seto # Taskforce: ACS Supplemental Oxygen in ACS 887.
Advertisements

Dallas 2015 TFQO: Allan de Caen COI#38 EVREV 1: Melissa Parker COI#259 EVREV 1: Takanari Ikeyama COI#235 Taskforce: Pediatrics Peds 820 : The use of fluids.
Dallas 2015 TFQO: Myra Wyckoff #COI EVREV 1: Myra Wyckoff #COI EVREV 2: Lindsay Mildenhall #107 Taskforce: NRP NRP: 605 Two thumb verses two finger.
Dallas 2015 TFQO: Marya Strand, MD, MS; COI#222 EVREV 1: Marya Strand, MD, MS; COI#222 EVREV 1: Takahiro Sugiura, MD; COI#224 Taskforce: NLS Umbilical.
Dallas : CPAP and IPPV In spontaneously breathing preterm infants with respiratory distress requiring respiratory support in the delivery room,
Chicago 2014 TFQO: Kee-Chong Ng (#COI = 113) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: EVREVs: de Almeida, Maria Fernanda COI# Trevisanuto, Daniele COI# Taskforce: Neonatal Warming Adjunts #599 Among preterm neonates who.
Dallas 2015 TFQO: David Stanton COI 328 EVREVs: Volker Wenzel COI 253& Emmanuelle Bourdon COI 333 Taskforce: BLS Passive ventilation techniques.
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI 261 EVREV 2: Daniel Pichel COI # 513 Taskforce: ACS ACS 335: Pre-hospital ADP- Receptor.
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Charles Deakin COI #221 Taskforce: ALS ALS 714 : Advanced airway placement (SGA.
Peds-818: Pediatric Early Warning Scores
Dallas 2015 TFQO: Vinay Nadkarni MD COI#249 EVREV 1: Graeme Maclaren MBBS COI#98 EVREV 2: Ravi Thiagarajan MBBS, MPH COI#149 Taskforce: PALS Peds 819 :
Dallas 2015 TFQO: Karen Woolfrey COI #261 EVREV 1: Karen Woolfrey COI #261 EVREV 2: Daniel Pichel COI #513 Taskforce: ACS ACS 873: Pre-hospital STEMI Activation.
Dallas 2015 TFQO: Jeffry Pearlman COI# 187 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP.
Dallas 2015 TFQO: EVREVs: Aaron Donoghue / Jonathan Duff Taskforce: EIT Teaching Compression-Only CPR.
Dallas 2015 TFQO: Masanori Tamura #147 EVREV 1: Masanori Tamura #147 EVREV 2: Susan Niermeyer #252 Delayed Cord Clamping in Preterm Infants Including those.
ACS and Thrombosis in the Emergency Setting
NRP: 862: Use of Feedback CPR Devices for Neonatal Cardiac Arrest NRP: 863: Use of Feedback CPR Devices to detect ROSC for Neonatal Cardiac Arrest TFQO:
The impact of pre-hospital thrombolytic treatment on re-infarction rates: Analysis of the Myocardial Infarction National Audit project (MINAP) Dr Simon.
EVIDENCE BASED MEDICINE Effectiveness of therapy Ross Lawrenson.
Chicago 2014 TFQO: Peter Meaney #COI 149 EVREV 1: Richard Aickin #COI 153 EVREV 1: Peter Meaney #COI 149 Taskforce: Pediatrics Resuscitation fluids (Peds)
Dallas 2015 TFQO: Marilyn Escobedo COI#78 EVREV 1: Marilyn Escobedo COI#78 EVREV 2: Henry Lee COI#135 Taskforce: NRP Babies born to mothers who are hypothermic.
Dallas 2015 TFQO: Robert Greif EVREVs: Jan Breckwoldt, Henrik Fischer Taskforce: Education Implementation and Training (EIT) AED training methods.
Dallas 2015 TFQO: Enrique Udaeta COI# 239 EVREV 1: Enrique Udaeta COI# 239 EVREV 1: Edgardo Ezslyd COI# 277 Taskforce: NRP Laryngeal Mask Airway (NRP 618)
Dallas 2015 TFQO: EVREVs: Guinsburg, Ruth COI# McGowan, Jane COI# Taskforce: Neonatal Apgar Zero #896 In infants ≥36 weeks GA with an Apgar score.
Dallas 2015 TFQO: Name EVREV 1: Jonathan Wyllie COI #282 EVREV 1: Jeff Perlman COI #262 Taskforce: Newborn Temperature Maintenance in the Delivery room.
Chicago 2014 TFQO: Nikolaos Nikolaou COI#253 EVREV 1: Nikolaos Nikolaou COI#253 EVREV 2: Farzin BeyguiCOI#202 Taskforce: ACS STEMI transfer PCI vs. FL.
Dallas 2015 TFQO: Anne-Marie Guerguerian # 97 EVREV1: Anne-Marie Guerguerian # 97 EVEREV2: Ericka Fink # 83 Taskforce: PEDS Peds 407 : ECMO for pediatric.
Dallas 2015 TFQO: Darren Walters EVREVs: EVREV 1: Darren Walters COI #422 EVREV 2: Chris Ghaemmaghami COI #89 Taskforce: Acute Coronary Syndrome Fibrinolytic.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
First Aid 801: Stroke Recognition
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 4 (maximum) using standard.
Dallas 2015 TFQO: David Boyle COI #26 EVREV 1: David Boyle #COI#26 EVREV 1: Jane McGowan #370 Taskforce: Neonatal Ventilation Strategies in the DR (NRP.
Dallas 2015 TFQO: Name and #COI EVREV 1: Name and #COI Taskforce: Name Insert Short PICO title (including unique PICO ID#) Total of 6 (maximum) using standard.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Dallas 2015 TFQO: Michael Sayre COI #400 EVREV 1: Mohamud Daya COI #327 EVREV 2: Jan-Thorsten Gräsner COI #230 Taskforce: BLS BLS 363: CPR Prior to Defibrillation.
Chicago 2014 TFQO: Charles Deakin #329 EVREV 1: Asger Granfeldt COI #63 EVREV 2: Bo Lofgren COI #363 Taskforce: ALS ALS 571 : Ventilation strategy post-ROSC.
Dallas 2015 TFQO: Allan de Caen COI #38 EVREV 1: Tia Raymond COI #153; EVREV 2: Jonathan Egan COI #44 Taskforce: Peds The role of invasive vascular monitoring.
Dallas 2015 TFQO: Kee-Chong Ng (#COI = 170) EVREV 1: Gene Ong (#COI = 118) EVREV 2: Jos Bruinenberg (#COI = 19) Taskforce: Pediatric Taskforce The Long.
Dallas 2015 TFQO: Vinay Nadkarni #375 EVREV 1: Vinay Nadkarni #375 EVREV 1: Dave Kloeck #126 Taskforce: Paeds Paed 424: Vasopressors in Paediatric cardiac.
Chicago 2014 Pediatric RRT/MET Teams #397 TFQO: Dianne Atkins COI #7 EVREV 1: Dianne Atkins EVREV 2: Kee Chong Ng COI #113 Taskforce: Peds.
TFQO: Jasmeet Soar #COI 272 EVREV 1: Jasmeet Soar #COI 272 EVREV 2: Michael Donnino #COI 222 Taskforce: ALS ALS 448 OXYGEN DOSE AFTER ROSC IN ADULTS 3.
Dallas 2015 TFQO: Maaret Castrén #320 EVREV 1: Christian Vaillancourt #416 EVREV 2: Michael Sayre #400 Taskforce: BLS BLS 359: Dispatcher Instructions.
Dallas 2015 TFQO: Jan Jensen COI #115 EVREVs: Jan Jensen COI #115 Richard N. Bradley COI #151 Taskforce: First Aid 769: Hemostatic Dressings.
Dallas 2015 TFQO: Monica Kleinman COI #353 EVREV 1: Janice Tijssen COI#232 EVREV 2: Javier Urbano COI#240 Taskforce: Peds Peds 815: Pediatric goal-directed.
Dallas 2015 TFQO: Judith Finn EVREVs: Judith Finn #227 / Dion Stub #COI Taskforce: EIT Cardiac Arrest Centres.
Dallas 2015 TFQO: Michael W. Donnino COI# EVREVs: Katherine M. Berg COI# Lars W. Andersen COI# Taskforce: ALS Ultrasound During CPR.
Dallas 2015 TFQO: Jan Jensen COI #115 EVREV: Michael Reilly COI #193 Taskforce: First Aid First Aid 768: Use of Tourniquet.
Dallas 2015 TFQO: Koen Monsieurs 372 EVREV 1: Koen Monsieurs 372 EVREV 2: Ahamed Idris 349 Taskforce: BLS BLS366 Chest Compression Depth (adults)
Dallas 2015 TFQO: Jerry Nolan #310 EVREV 1: Jerry Nolan COI #301 EVREV 2: Jan-Thorsten Graesner COI #150 Taskforce: ALS ALS 783 : Advanced versus basic.
Dallas 2015 TFQO: Robert Greif EVREVs: Dana Edelson, COI #334 Robert Greif, COI #344 Taskforce: EIT EIT 645: Debriefing of resuscitation performance.
Dallas 2015 TFQO: Hiroshi Nonogi #254 EVREVs: Hiroshi Nonogi #254 Tony Scott #138 Taskforce: ACS Fibrinolytic and immediate PCI for STEMI 882.
Dallas 2015 TFQO: S. Velaphi EVREV 1: N. Singhal COI #213 EVREV 2: S. Velaphi COI #242 EVREV 3: H. Ersdal – COI # 76 Taskforce: NLS Prognosis: In newborn.
Dallas 2015 TFQO: Karen Woolfrey #COI 261 EVREV 1: Karen Woolfrey # COI 261 EVREV 2: Daniel Pichel #COI 513 Taskforce: ACS ACS 872: Pre-hospital Diversion.
Dallas 2015 TFQO: Name EVREVs: Names and #COI Taskforce: Name Insert Short PICO title Total of 12 (no studies) to 20 slides (maximum) using standard format.
Dallas 2015 TFQO: Jonathan Witt (COI #418) EVREVs: Steve Lin (COI #137), Thomas Pellis (COI #186) and Katie Dainty (COI #) Taskforce: ALS ALS 428 : Antiarrhythmic.
Chicago 2014 TFQO: Clifton Callaway # EVREV 1: Janice Zimmerman # EVREV 2: Jonathan Sullivan COI # Taskforce: ALS ALS 790 : Induced Hypothermia.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Dallas 2015 TFQO: Jasmeet Soar #COI 409 EVREV 1: Jasmeet Soar #COI 409 EVREV 2: Anthony Lagina #COI 357 Taskforce: ALS ALS 889 OXYGEN DOSE DURING CPR IN.
Dallas 2015 TFQO: Michael Donnino #222 EVREV 1: Joshua Reynolds COI #265 EVREV 2: Katherine Berg COI #10 Taskforce: ALS ALS 790 : Induced Hypothermia.
A Clinical profile of patients enrolled in the Pakistan ACS registry
Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:
Systolic Blood Pressure Intervention Trial (SPRINT)
STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES
European Heart Association Journal 2007 April
Global Registry of Acute Coronary Events: GRACE
China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.
MRRs and EMRRs for women with ACS
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Chicago 2014 TFQO: Darren Walters COI #317 EVREV 1: Darren Walters COI #317 EVREV 2: Chris Ghaemmaghami COI #60 Taskforce: Acute Coronary Syndrome In STEMI (P), does fibrinolytic therapy prior to hospital arrival (I), compared with fibrinolytic therapy after hospital arrival (C), change outcomes(O)? ACS 338

Chicago 2014 COI Disclosure Chris Ghaemmaghami COI #60 Commercial/industry Potential intellectual conflicts Darren Walters COI #317 Commercial/industry Nil Potential intellectual conflicts Editor IJC, HLC

Chicago Treatment Recommendation In patients with STEMI diagnosed in the prehospital setting, reperfusion may be achieved by administration of fibrinolytics by healthcare providers in the field. Alternately, fibrinolytic therapy may be administered on arrival at hospital. If fibrinolysis is chosen as the reperfusion strategy, it should be started as soon as possible, ideally in the prehospital setting,and should be administered by paramedics, nurses, or doctors using well-established protocols, competency training programs, and quality assurance programs, under medical oversight.

Chicago 2014 C2015 PICO Population:Among adults who are suspected of having ST-elevation myocardial infarction outside of a hospital Intervention:does fibrinolytic therapy prior to hospital arrival Comparison:compared with fibrinolytic therapy after hospital arrival Outcomes:change death 9-Critical ICH 8- Critical revascularization 7-Critical major bleeding 6-Important stroke 6-Important reinfarction 5-Important

Chicago 2014 Inclusion/Exclusion & Articles Found (“myocardial infarction”[MH] OR AMI[ti] OR “STEMI”[TI] OR “st-elevation”[ti] OR “st elevation”[ti] OR “ST- segment”[TI] OR “ST segment”[TI] OR “infarct*”[ti] OR “myocardial ischemia”[MH] OR “coronary thrombosis”[MH]) AND (“myocardial reperfusion”[MH] OR fibrinoly*[tiab] OR fibrinolytic agents[MH] OR thrombolytic therapy[MH] OR thromboly*[tiab] OR reteplase[TI] OR anistreplase[TI] OR ER-TIMI[TI] OR “tissue plasminogen activator”[TI] OR “tissue plasminogen activator”[MH] OR alteplase[TI] OR rt-PA[TI] OR TPA[TI] OR tenecteplase[TI] OR streptokinase[TI] OR APSAC[TI]) AND (""Emergency medical technicians""[MH] OR ""pre-hospital""[TI] OR ""prehospital""[TI] OR ""ambulance""[TI] OR “ambulances”[MH] OR ""paramedic*""[TI] OR “Emergency medical services”[MH] OR “EMS”[TI] OR “EMT”[TI] OR “out-of- hospital”[TI] OR “out of hospital”[TI] OR “emergency physician*”[TI] OR mobile[TI] OR “before hospital”[TI]) NOT (“animals”[MH] NOT “humans”[MH]) NOT (“editorial”[PT] OR “letter”[PT] OR “comment”[PT] OR “review”[PT] OR “practice guideline”[PT]) NOT ""score""[TI] AND ((("randomized controlled trial"[PT] OR “controlled clinical trial”[PT] OR “clinical trial”[PT] OR “comparative study”[PT] OR random*[TIAB] OR controll*[TIAB] OR “intervention study”[TIAB] OR “experimental study”[TIAB] OR “comparative study”[TIAB] OR trial[TIAB] OR evaluat*[TIAB] OR “Before and after”[TIAB] OR “interrupted time series”[TIAB]) NOT ("animals"[MH] NOT (animals[MH] AND "humans"[MH]))) OR ("Epidemiologic Studies"[Mesh] OR “case control”[TIAB] OR “case-control”[TIAB] OR ((case[TIAB] OR cases[TIAB]) AND (control[TIAB] OR controls[TIAB)) OR “cohort study”[TIAB] OR “cohort analysis”[TIAB] OR “follow up study”[TIAB] OR “follow-up study”[TIAB] OR “observational study”[TIAB] OR “longitudinal”[TIAB] OR “retrospective”[TIAB] OR “cross sectional”[TIAB] OR “cross-sectional”[TIAB] OR questionnaire[TIAB] OR questionnaires[TIAB] OR questionnaires[TIAB] OR survey[TIAB]))) NOT ("letter"[pt] OR "comment"[pt] OR "editorial"[pt]) 279 papers Metanalysis 2 RCTs, 3 non-RCTs 60 excluded

Chicago 2014 Previousmet analysis by Morrison JAMA 2000 (6 RCTs) EMIP 1993 included NSTEMI unable to sub stratify data GREAT 1992 no ST elevation –suspicion of STEMI Roth 1990 used alternate monthly rotational allocations Cochrane review includes 3 studies Reviewed the worksheet ACS-018B 2010 COSTAR 32 studies. Inclusion/Exclusion & Articles Found

Chicago Proposed Treatment Recommendations We suggest using pre-hospital fibrinolysis in comparison to in-hospital fibrinolysis for STEMI to reduce the risk of all cause in-hospital mortality based on a low level of evidence.

Chicago 2014 Risk of Bias in studies RCT bias assessment StudyYearDesign Total Patien ts Populati on Industry Funding Allocation: Generation Allocation: Concealment Blinding: Participants Blinding: Assessors Outcome: Complete Outcome: Selective Other Bias Castaigne 1989RCT100OHCA NoUnclearHigh highHighLowUnclear Schofer 1990RCT78OHCA NolowLow UnclearHighLow Weaver 1993RCT360OHCA nolowLowHighLowUnclearHighLow

Chicago 2014 Forest plot and risk of bias

Chicago 2014 Forest Plot bleeding

Chicago 2014 Forrest plot ICH

Chicago 2014 Forrest plot CVA

Chicago 2014 Evidence profile table(s)

Chicago 2014 Evidence profile table(s)

Chicago 2014 Evidence profile table(s)

Chicago 2014 Reviewed non randomised studies studies First pass 7 studies in detail Armstrong 2010STREAM vs PCI Bata 2009WEST vs PCI Castle 2007retrospective decision analsyis Khan 2009actuarial survival only Koeth 2009 eligible for rct vs ineligible Smith 2011 no outcomes paramedic decisions Zeymer 2009non RCT cohort comparison

Chicago 2014 Forrest plot incl non RCT Mortality

Chicago 2014 Forrest plot incl non RCT Bleeding CVA

Chicago 2014 Re infarction Forrest plot incl non RCT

Chicago 2014 Proposed Consensus on Science statements Insert Summary statement(s) from SEERs* For the important outcome of “all cause hospital mortality” we have identified low quality evidence (downgraded for bias allocation and concealment) from three RCTs enrolling 538 patients showing benefit (OR % CI 0.23 – 0.93). For the outcome of Bleeding complications a moderate level of evidence from 2 RCTS enrolling 438 patients showed no benefit (OR % CI ) For the outcome of stroke a low level of evidence from one study enrolling 360 patients showed no benefit (OR % CI ) For the outcome of intracranial haemorhage a moderate level of evidence was found from 2 studies enrolling 438 patients showed no benefit (OR % CI ) For other outcomes no evidence from RCTs was found. For reinfarction a low level of evidence from one non RCT showed enrolling 778 patients showed no benefit (OR % CI )

Chicago 2014 Draft Treatment Recommendations We suggest using pre-hospital fibrinolysis in comparison to in hospital fibrinolysis for STEMI to reduce the risk of all cause in hospital mortality based on a low level of evidence.